These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21515463)

  • 1. [Therapeutic effect of total glucosides of paeony on lupus nephritis in MRL/lpr mice].
    Ding ZX; Yang SF; Wu QF; Lu Y; Chen YY; Nie XL; Jie HY; Qi JM; Wang FS
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Apr; 31(4):656-60. PubMed ID: 21515463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
    Zhai ZF; Zhou CL; Zhong BY; Ao JH; Hao F
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):406-10. PubMed ID: 18581896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
    Sadanaga A; Nakashima H; Masutani K; Miyake K; Shimizu S; Igawa T; Sugiyama N; Niiro H; Hirakata H; Harada M
    Arthritis Rheum; 2005 Dec; 52(12):3987-96. PubMed ID: 16320345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
    J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands
    Liang CL; Jiang H; Feng W; Liu H; Han L; Chen Y; Zhang Q; Zheng F; Lu CJ; Dai Z
    Front Immunol; 2021; 12():683249. PubMed ID: 34290705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversing interleukin-2 inhibition mediated by anti-double-stranded DNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice.
    Song YC; Tang SJ; Lee TP; Hung WC; Lin SC; Tsai CY; Ng WV; Wu MF; Sun KH
    Arthritis Rheum; 2010 Aug; 62(8):2401-11. PubMed ID: 20506162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral administration of malathion on the course of disease in MRL-lpr mice.
    Rodgers KE
    J Autoimmun; 1997 Aug; 10(4):367-73. PubMed ID: 9237800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
    J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.
    Anders HJ; Vielhauer V; Eis V; Linde Y; Kretzler M; Perez de Lema G; Strutz F; Bauer S; Rutz M; Wagner H; Gröne HJ; Schlöndorff D
    FASEB J; 2004 Mar; 18(3):534-6. PubMed ID: 14734643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
    Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
    J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation was involved in total glucosides of paeony regulating ERα for the treatment of female systemic lupus erythematosus mice.
    Li M; Jiang A
    J Pharmacol Sci; 2019 Jun; 140(2):187-192. PubMed ID: 31345653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis.
    Hung WT; Chen YM; Lan JL; Chen HH; Chen YH; Chen DY; Hsieh CW; Wen MC
    Lupus; 2011 Nov; 20(13):1404-10. PubMed ID: 21946514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice.
    Fujii T; Okada M; Fujita Y; Sato T; Tanaka M; Usui T; Umehara H; Mimori T
    J Autoimmun; 2009 Sep; 33(2):125-34. PubMed ID: 19596182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice.
    Tan H; Zhao J; Wang S; Zhang L; Wang H; Huang B; Liang Y; Yu X; Yang N
    Int Immunopharmacol; 2012 Dec; 14(4):401-9. PubMed ID: 22922317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
    Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
    J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice.
    Hu N; Long H; Zhao M; Yin H; Lu Q
    Scand J Rheumatol; 2009; 38(6):464-71. PubMed ID: 19922023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combining ACE inhibitor and statin in lupus-prone mice.
    Shimazu H; Kinoshita K; Hino S; Yano T; Kishimoto K; Nagare Y; Nozaki Y; Sugiyama M; Ikoma S; Funauchi M
    Clin Immunol; 2010 Aug; 136(2):188-96. PubMed ID: 20403731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
    Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
    Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice.
    Sadanaga A; Nakashima H; Akahoshi M; Masutani K; Miyake K; Igawa T; Sugiyama N; Niiro H; Harada M
    Arthritis Rheum; 2007 May; 56(5):1618-28. PubMed ID: 17469144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.